Lack of TET2 gene mutation in Tunisian acute myeloid leukemia
Introduction/Background/Significance: Acute myeloid leukemia (AML) is a malignancy associated with altered myeloid lineage precursor hyperplasia and accompanied by different genetic mutations. The impact of Tet oncogene family member 2 (TET2) mutations on the prognosis of AML has been documented. TET2 serves as an important prognostic marker as well as a potential therapeutic target. In LMICs there is limited data presently reported.
Materials and Methods/Case Presentation/Objective: This study was carried out to assess the prevalence and clinical impact of functional subtypes of TET2 mutation in Tunisian acute myeloid leukemia (AML).
A one-year retrospective study was carried out at the Hospital University of Sfax, south of Tunisia.
A multiplex PCR and Sanger sequencing were performed using a high-fidelity DNA polymerase.
Results/Description/Main Outcome Measures: Forty patients were enrolled. The sex ratio (M/F) was 0.7. The median age was 43 years [5-66 years]. At the molecular level, no mutation of the TET2 gene was detected.
Conclusions: Our data on the Tunisian population suggest that the TET2 mutation is not common in Tunisian AML and thus does not affect clinical outcome. A larger study of the genetic landscape is mandatory to elucidate prognosis impact in AML.
